Making money in several ways
In Minnesota müssen Pharmafirmen ihre Zahlungen an Ärzte offenlegen. Die NY Times hat sich das Ergebnis genauer angesehen.
Jamie Reidy, a drug sales representative for Pfizer Inc. and Eli Lilly & Company who was fired in 2005 after writing a humorous book about his experiences, said drug makers seduced doctors with escalating financial inducements that often start with paid trips to learn about a drug. “If a doctor says that he got flown to Maui, stayed at the Four Seasons — and it didn’t influence him a bit? Please,” Mr. Reidy said.
...
“You’re making him money in several ways,” said Gene Carbona, who left Merck as a regional sales manager in 2001. “You’re paying him for the talk. You’re increasing his referral base so he’s getting more patients. And you’re helping to develop his name. The hope in all this is that a silent quid quo pro is created. I’ve done so much for you, the only thing I need from you is that you write more of my products.”
...
“You’re making him money in several ways,” said Gene Carbona, who left Merck as a regional sales manager in 2001. “You’re paying him for the talk. You’re increasing his referral base so he’s getting more patients. And you’re helping to develop his name. The hope in all this is that a silent quid quo pro is created. I’ve done so much for you, the only thing I need from you is that you write more of my products.”
[Pharmaindustrie]
| Autor: strappato 2007-03-21 Link (3 Kommentare) Ihr Kommentar |
kelef 2007-03-22
Die wissen, dass da Wiederholungstäter dabei sind:
http://nymag.com/daily/intel/2007/03/rost_takes_another_shot_at_big.html
Pfizer executive turned whistleblower Peter Rost is back doing what he does best: skewering his erstwhile industry. Rost was notoriously banished from Big Pharma after exposing tax fraud at Wyeth and illegal marketing at Pfizer; his tell-all The Whistleblower came out last year. His new project, a novel called The Wolfpack, was sold last week to Pagina AB in Europe. (It's now being shopped to several publishers in New York.) "I wrote the story because I wanted to reveal the thinking inside a corporation, using the thriller format," Rost says of his "Grisham-style" crime drama. The story follows a fictional drug company that develops a biological weapon and murders its enemies. Although Rost insists none of the characters are based on former colleagues, the new book is about "just how far corporate executives may be willing to go and what happens when one guy stands up to them." Fiction, huh? —Jake Whitney
http://nymag.com/daily/intel/2007/03/rost_takes_another_shot_at_big.html
Pfizer executive turned whistleblower Peter Rost is back doing what he does best: skewering his erstwhile industry. Rost was notoriously banished from Big Pharma after exposing tax fraud at Wyeth and illegal marketing at Pfizer; his tell-all The Whistleblower came out last year. His new project, a novel called The Wolfpack, was sold last week to Pagina AB in Europe. (It's now being shopped to several publishers in New York.) "I wrote the story because I wanted to reveal the thinking inside a corporation, using the thriller format," Rost says of his "Grisham-style" crime drama. The story follows a fictional drug company that develops a biological weapon and murders its enemies. Although Rost insists none of the characters are based on former colleagues, the new book is about "just how far corporate executives may be willing to go and what happens when one guy stands up to them." Fiction, huh? —Jake Whitney
na ja, andererseits, im journalismus heisst es: a g'schicht is a g'schicht. wäre das angebot an interessanten geschichten in der pharmabranche nicht so gross, gäbe es auch nicht so viele leut' die bücher darüber schreiben, blogs führen etc.. hat alles immer zwei seiten, und von nix kommt auch nix.
>> Kommentieren
